Epigral is a chemical company that turned a commodity problem into a strategic asset: instead of selling the chlorine and hydrogen it makes, it feeds them into a growing chain of higher-value specialty products, all from a single, tightly connected factory complex in Gujarat. The company was born in 2007 as a subsidiary of Meghmani Organics, listed independently in 2021, and rebranded as Epigral in 2023 - a name that signals its ambition to be a global, multi-product chemical conglomerate. That recurring approach of building downstream derivatives that consume its own raw materials is the logic behind every plant it has added, transforming it from a basic chemical maker into an integrated specialty platform.
Business segments
Two deeply connected businesses that feed each other - a foundational chlor-alkali engine that produces the raw materials, and a derivatives engine that consumes them to make higher-value specialty chemicals, with the second growing faster and driving the company's future.
1. Chlor-Alkali: the feedstock engine that makes everything else possible
Caustic soda, chlorine and hydrogen are produced at scale, but their real job is to be consumed captively by the company's own downstream plants rather than sold as commodities.
- Chlorine is the strategic prize - the proportion of chlorine consumed inside the complex rose from 72% to 75% in the last year, with a target of roughly 95% by 2028, because every molecule fed into a derivative plant earns more than selling it as a commodity.
- Caustic soda still reaches outside customers - it is sold as lye and flakes to industries like alumina, textiles, soaps and water treatment, and its revenue contribution has deliberately fallen from 75% to 48% over five years as derivatives take over.
- Captive power keeps costs predictable - a 132 MW captive power plant and a growing hybrid renewable-energy setup (targeting 38 MW) supply the majority of electricity needs, with green power costing about 30% less per unit than grid electricity.
2. Derivatives and Specialty Chemicals: where the value multiplies
Chlorine and hydrogen are transformed into a portfolio of import-substitute products - CPVC, epichlorohydrin, chlorotoluenes and more - that serve industries from construction to pharmaceuticals and command higher, more stable realisations.
- CPVC resin is the flagship - at 75,000 tonnes per year it is already the world's largest single-location plant, with another 75,000 tonnes approved, because India imports 95% of its CPVC demand and domestic pipe manufacturers need a reliable local supplier.
- Epichlorohydrin replaces imports with a greener process - India's first ECH plant uses glycerin, a biodiesel by-product, instead of petroleum-based propylene, cutting global-warming potential by more than 60% while serving epoxy-resin makers and windmill-blade manufacturers.
- Chlorotoluenes open the pharma and agrochemical door - commissioned in March 2025, this 15,000-tonne plant makes specialty intermediates that go through multi-year customer approvals, creating sticky, long-term relationships once validated.
- Chloromethanes and hydrogen peroxide fill out the portfolio - a 50,000-tonne chloromethanes plant supplies refrigerants and PTFE makers, while 60,000 tonnes of hydrogen peroxide serves paper, textiles and effluent treatment, together adding breadth without diluting the integration logic.
- The mix is shifting decisively - derivatives have grown from zero to 52% of revenue in eight years, with a target of roughly 70% by 2028, because every downstream product captures the margin that would otherwise be lost in selling raw chlorine.
Research and Development
A dedicated R&D centre in Ahmedabad invents the next molecules, particularly inside the chlorotoluene ecosystem, so the company keeps moving further from commodities and closer to custom-manufactured specialty intermediates.
- Recognised by the government's DSIR - the 14,374-square-metre facility was built with an initial investment of ₹30 crore and houses 25 scientists working on electrolysis, hydrogenation, ring chlorination and nine other reaction types.
- Pilot plants shorten the path to revenue - a pilot facility is being built to produce samples for customer validation of new chlorotoluene derivatives and CPVC grades, cutting the time between full-scale commissioning and commercial orders.
- Import substitution is the innovation filter - the team targets molecules currently imported from China, Japan and Europe for Indian pharma and agrochemical customers, turning global supply-chain anxiety into a local opportunity.
Group structure and partners
Epigral is a single listed entity with a concentrated promoter holding, two captive renewable-energy partnerships, and a newly incorporated subsidiary that signals further expansion.
- Renewable power comes through two associate SPVs - Epigral owns 26% in each of two wind-solar hybrid ventures (one operational at 18.34 MW, one under construction at 19.80 MW) that supply power exclusively to the Dahej complex under 25-year captive arrangements.
- A new subsidiary points to the next chapter - Epigral Advanced Materials Limited was incorporated in July 2026 as a wholly owned subsidiary with the objective of manufacturing chemicals, suggesting the single-complex model may eventually extend to new sites.